Selumetinib monotherapy, and combination with anti-CTLA-4, led to significant decreases in tumor-infiltrating gMDSC/neutrophil when compared to control or anti-CTLA-4 alone (Fig. 4b, panel I); suggesting that MEK inhibition may improve the tumor microenvironment by reducing immunosuppressive cell types. This evidence concerns the gene MAP2K7 and neoplasm.